Outcome of primary trabeculectomy with adjunctive bevacizumab versus 5‐fluorouracil: 24‐month results

• Published in: Acta ophthalmologica (Oxford, England) Vol. 88; no. s246
• Main Authors: ZARNOWSKI, T, JURKOWSKA‐DUDZINSKA, J, KOSIOR‐JARECKA, E
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.09.2010
• ISSN: 1755-375X; 1755-3768
• DOI: 10.1111/j.1755-3768.2010.3152.x

Purpose Purpose. The aim of the study was to compare the effect of bevacizumab and 5‐fluorouracil on the efficacy and safety of trabeculectomy. Methods Material and methods. Nonrandomized, prospective, interventional case series study was scheduled for 62 patients undergoing primary trabeculectomy in Department of Ophthalmology, Medical University, Lublin, Poland for primary open angle glaucoma (POAG) and pseudoexfoliative glaucoma (PEXG). In group 1 that consisted of 30 patients (21 POAG, 9 PEXG) trabeculectomy with adjunctive 5‐FU was performed (4 min. intraoperative application). In group 2 that consisted of 32 patients (21 POAG, 11 PEXG) trabeculectomy enhanced by subconjunctival bevacizumab application (immediately before and after surgery, 1 and 7 days after surgery) was performed. Results Results. Mean IOP before 5‐FU‐augmented trabeculectomy was 28.0±8.0 mmHg, and before bevacizumab‐augmented trabeculectomy was 27.8±9.5 mmHg (p=0.96). After 6 months mean IOP was 13.4±4.6 mmHg in the 5‐FU group and 13.7±5.2 mmHg in the bevacizumab group (p=0.39). After 12 months mean IOP was 13.6±4.4 mmHg in the 5‐FU group and 14.7±4.7 mmHg in the bevacizumab group (p=0.96). After 24 months mean IOP in 5‐FU group valued 13.4±3.8 mmHg and in Avastin group 15.0±3.3mmHg (p=0.24). No differences were noted with respect to corneal endothelial density, visual field indices and postoperative complications. Conclusion Conclusions. 24‐month results comparing the outcome of bevacizumab and 5‐FU augmented trabeculectomy did not show significant difference between the application of bevacizumab and 5‐FU.